Ranbaxy Laboratories has reported results for second quarter ended June 30, 2012.
On standalone basis, the company has reported a net loss of Rs 925.66 crore for the quarter ended June 30, 2012 against net profit of Rs 150.37 crore for the corresponding period last fiscal. However, total income increased by 22.23% at Rs 1586.98 crore during the quarter under review from Rs 1298.34 crore in the year-ago period.
On Consolidated basis, the company has reported a net loss of Rs 585.72 crore for the quarter ended June 30, 2012 against net profit of Rs 243.23 crore for the corresponding period last fiscal. However, total income increased by 54.82% at Rs 3298.21 crore during the quarter under review from Rs 2130.31 crore in the year-ago period.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: